Near-Infrared Light-Controlled Nitric Oxide Delivery Combined with In Situ Activated Chemotherapy for Enhanced Multimodal Therapy DOI

Bing Ren,

Jing Liu, Yi Wang

et al.

ACS Applied Bio Materials, Journal Year: 2025, Volume and Issue: unknown

Published: April 8, 2025

Development of nanoplatforms with in situ activation for chemotherapy represents a promising modality biomedical application. Herein, multifunctional nanoplatform, CMS@DTC@PDA@RuNO@FA (abbreviated as CDPNF NPs), was developed highly efficient antitumor therapy, which diethyldithiocarbamate (DTC)-loaded mesoporous Cu2MoS4 (CMS) nanoparticles were covered by polydopamine (PDA) layers and further covalently modified NO donor (RuNO) folic acid (FA)-directing moiety. Under the mild acidic tumor microenvironment (TME), NPs co-liberated DTC Cu2+ site, where formation cytotoxic Cu(DTC)2 complex effectively killed cells. Furthermore, under near-infrared (NIR) light irradiation, could deliver nitric oxide (NO) produce superoxide anions (O2•-), followed more toxic peroxynitrite (ONOO-), led to promoted cell apoptosis. 1064 nm NIR vivo experiments demonstrated an impressively high inhibition rate (∼97%) while good biocompatibility. This work activated approach precision medicine that might imply its potential clinical applications.

Language: Английский

NIR-activatable proenzyme DSF/CuS@M for synergistic in situ chemotherapy/CDT/PTT/cuproptosis-based antitumor therapy DOI

Lushuang Xu,

Qinyue Chen,

Yangwei Qian

et al.

Chemical Engineering Journal, Journal Year: 2025, Volume and Issue: unknown, P. 161733 - 161733

Published: March 1, 2025

Language: Английский

Citations

0
Near-Infrared Light-Controlled Nitric Oxide Delivery Combined with In Situ Activated Chemotherapy for Enhanced Multimodal Therapy DOI

Bing Ren,

Jing Liu, Yi Wang

et al.

ACS Applied Bio Materials, Journal Year: 2025, Volume and Issue: unknown

Published: April 8, 2025

Development of nanoplatforms with in situ activation for chemotherapy represents a promising modality biomedical application. Herein, multifunctional nanoplatform, CMS@DTC@PDA@RuNO@FA (abbreviated as CDPNF NPs), was developed highly efficient antitumor therapy, which diethyldithiocarbamate (DTC)-loaded mesoporous Cu2MoS4 (CMS) nanoparticles were covered by polydopamine (PDA) layers and further covalently modified NO donor (RuNO) folic acid (FA)-directing moiety. Under the mild acidic tumor microenvironment (TME), NPs co-liberated DTC Cu2+ site, where formation cytotoxic Cu(DTC)2 complex effectively killed cells. Furthermore, under near-infrared (NIR) light irradiation, could deliver nitric oxide (NO) produce superoxide anions (O2•-), followed more toxic peroxynitrite (ONOO-), led to promoted cell apoptosis. 1064 nm NIR vivo experiments demonstrated an impressively high inhibition rate (∼97%) while good biocompatibility. This work activated approach precision medicine that might imply its potential clinical applications.

Language: Английский

Citations

0